Advances in the Development of Phosphodiesterase-4 Inhibitors
- 7 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (19), 10594-10617
- https://doi.org/10.1021/acs.jmedchem.9b02170
Abstract
Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs in market. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4.Funding Information
- Department of Science and Technology of Sichuan Province (2017JQ0038)
- National Natural Science Foundation of China (81703457)
- Sichuan Provincial People's Hospital (2016LZ03)
This publication has 120 references indexed in Scilit:
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP PhosphodiesterasesCell, 2012
- GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic dosesBritish Journal of Pharmacology, 2011
- Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthmaJournal of Allergy and Clinical Immunology, 2010
- The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthmaRespiratory Research, 2010
- Dual Inhibitors of Phosphodiesterase-4 and Serotonin ReuptakeJournal of Medicinal Chemistry, 2009
- Design, Synthesis, and Structure−Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones as Highly Potent and Selective Phosphodiesterase-4 InhibitorsJournal of Medicinal Chemistry, 2008
- Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?British Journal of Pharmacology, 2008
- The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10Journal of Molecular Biology, 2007
- An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary diseaseBritish Journal of Clinical Pharmacology, 2006